---
trial_id: 308
discovery_date: 2022-04-02 17:30:16.004442
date: 2022-04-02 17:30:16.004442
title: "A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis."
summary: |
  <p>EudraCT Number: 2004-000762-13<br />Sponsor Protocol Number: TV-5010/202<br />Sponsor Name: TEVA ITALIA srl<br />Start Date: 2004-08-31<br />Medical condition: Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit.<br />Disease: <br />Version: 15.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000762-13/IT">IT</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000762-13'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2004-000762-13<br />Sponsor Protocol Number: TV-5010/202<br />Sponsor Name: TEVA ITALIA srl<br />Start Date: 2004-08-31<br />Medical condition: Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit.<br />Disease: <br />Version: 15.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000762-13/IT">IT</a> (Completed)</p>